[1]
|
Kaplan, G.G. and Ng, S.C. (2017) Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology, 152, 313-321.E2. https://doi.org/10.1053/j.gastro.2016.10.020
|
[2]
|
Ng, S.C., Bernstein, C.N., Vatn, M.H., Lakatos, P.L., Loftus Jr., E.V., Tysk, C., O’Morain, C., Moum, B. and Colombel, J.F. (2013) Geographical Variability and Environmental Risk Factors in Inflammatory Bowel Disease. Gut, 62, 630-649. https://doi.org/10.1136/gutjnl-2012-303661
|
[3]
|
Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W. and Kaplan, G.G. (2012) Increasing Inci-dence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. Gastroenterology, 142, 46-54.E42.
https://doi.org/10.1053/j.gastro.2011.10.001
|
[4]
|
Turner, D., Yerushalmi, B., Kori, M., Broide, E., Moz-er-Glassberg, Y., Shaoul, R., Kolho, K.L., Shteyer, E., Shamaly, H., Ledder, O., Cohen, S., Peleg, S., On, A. and Levine, A. (2017) Once- versus Twice-Daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. Journal of Crohn’s and Colitis, 11, 527-533. https://doi.org/10.1093/ecco-jcc/jjw180
|
[5]
|
李青云, 余海婷, 杜荣国. 益生菌联合美沙拉嗪治疗炎症性肠病的临床效果观察[J]. 智慧健康, 2022, 8(11): 111-113. https://doi.org/10.19335/j.cnki.2096-1219.2022.11.034
|
[6]
|
Fang, Y., Yan, C., Zhao, Q., Xu, J., Liu, Z., Gao, J., Zhu, H., Dai, Z., Wang, D. and Tang, D. (2021) Theroles of Microbial Products in the Development of Colorectal Cancer: A Review. Bioengineered, 12, 720-735.
https://doi.org/10.1080/21655979.2021.1889109
|
[7]
|
Mentella, M.C., Scaldaferri, F., Pizzoferrato, M., Gasbarrini, A. and Miggiano, G.A.D. (2020) Nutrition, IBD and Gut Microbiota: A Review. Nutrients, 12, Article 944. https://doi.org/10.3390/nu12040944
|
[8]
|
Yue, B., Yu, Z.L., Lv, C., Geng, X.L., Wang, Z.T. and Dou, W. (2020) Regulation of the Intestinal Microbiota: An Emerging Therapeutic Strategy for Inflammatory Bowel Disease. World Journal of Gastroenterology, 26, 4378-4393.
https://doi.org/10.3748/wjg.v26.i30.4378
|
[9]
|
Ma, C., Ascoytia, C., McCarrier, K.P., Martin, M., Feagan, B.G. and Jairath, V. (2018) Physicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease. Digestive Diseases and Sciences, 63, 2555-2563. https://doi.org/10.1007/s10620-018-5181-6
|
[10]
|
Berends, S.E., Strik, A.S., Löwenberg, M., D’Haens, G.R. and Mathôt, R.A.A. (2019) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clinical Pharmacokinetics, 58, 15-37.
https://doi.org/10.1007/s40262-018-0676-z
|
[11]
|
Loftus Jr., E.V., Kane, S.V. and Bjorkman, D. (2004) Systematic Review: Short-Term Adverse Effects of 5-Aminosalicylic Acid Agents in the Treatment of Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 19, 179-189.
https://doi.org/10.1111/j.0269-2813.2004.01827.x
|
[12]
|
Hauso, Ø., Martinsen, T.C. and Waldum, H. (2015) 5-Aminosalicylic Acid, a Specific Drug for Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 50, 933-941. https://doi.org/10.3109/00365521.2015.1018937
|
[13]
|
许国彩, 高燕, 周虹文. 美沙拉嗪在溃疡性结肠炎治疗过程中效果和安全性[J]. 中国老年学杂志, 2021, 41(21): 4703-4705.
|
[14]
|
Honda, K. and Littman, D.R. (2012) The Microbiome in Infectious Disease and Inflammation. Annual Review of Immunology, 30, 759-795. https://doi.org/10.1146/annurev-immunol-020711-074937
|
[15]
|
Yao, S., Zhao, Z., Wang, W. and Liu, X. (2021) Bifidobacterium Longum: Protection against Inflammatory Bowel Disease. Journal of Immunology Research, 2021, Ar-ticle ID: 8030297. https://doi.org/10.1155/2021/8030297
|
[16]
|
Pittayanon, R., Lau, J.T., Leontiadis, G.I., Tse, F., Yuan, Y., Surette, M. and Moayyedi, P. (2020) Differences in Gut Microbiota in Patients with vs without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology, 158, 930-946.E1. https://doi.org/10.1053/j.gastro.2019.11.294
|
[17]
|
Pei, L.Y., Ke, Y.S., Zhao, H.H., Wang, L., Jia, C., Liu, W.Z., Fu, Q.H., Shi, M.N., Cui, J. and Li, S.C. (2019) Role of Colonic Microbiota in the Pathogenesis of Ulcerative Colitis. BMC Gastroenterology, 19, Article No. 10.
https://doi.org/10.1186/s12876-019-0930-3
|
[18]
|
贠嘉威. 益生菌联合美沙拉嗪对溃疡性结肠炎的效果观察[J]. 中外女性健康研究, 2021(4): 107-108.
|
[19]
|
Dang, X., Xu, M., Liu, D., Zhou, D. and Yang, W. (2020) Assessing the Efficacy and Safety of Fecal Microbiota Transplantation and Probiotic VSL#3 for Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLOS ONE, 15, e0228846. https://doi.org/10.1371/journal.pone.0228846
|
[20]
|
李晶晶, 王小云, 李睿, 等. 溃疡性结肠炎运用益生菌联合美沙拉嗪治疗的效果分析[J]. 自我保健, 2022, 26(18): 146-148.
|
[21]
|
李娜, 蒋林伟, 张伟浩, 等. 用益生菌制剂对重症肺炎患者进行辅助治疗的效果探析[J]. 当代医药论丛, 2016, 14(20): 100-102.
|
[22]
|
Onoe, A., Matsuura, D., Terui, T., Ishii, N., Hashimoto, T. and Ochiai, T. (2017) Linear Immunoglobulin A/G Bullous Dermatosis Associated with Ulcerative Colitis. The Journal of Dermatology, 44, 1295-1298.
https://doi.org/10.1111/1346-8138.13934
|
[23]
|
霍惠子. 益生菌联合美沙拉嗪对溃疡性结肠炎患者的效果分析及对NGAL、MUC2蛋白影响[J]. 中国现代医生, 2021, 59(14): 111-114.
|
[24]
|
王芳, 张宁, 汪庆强, 等. 益生菌联合美沙拉嗪对小鼠溃疡性结肠炎模型外周血T淋巴细胞亚群及炎症细胞因子影响的研究[J]. 临床和实验医学杂志, 2021, 20(19): 2051-2055.
|
[25]
|
雷伟, 任贺庄, 屈锐, 等. 美沙拉嗪肠溶片联合益生菌治疗炎症性肠病的疗效及安全性观察[J]. 贵州医药, 2020, 44(11): 1774-1775.
|
[26]
|
陈静, 袁明勇, 张雪莲, 等. 美沙拉嗪联合益生菌治疗溃疡性结肠炎的疗效及其对炎性因子、应激蛋白和氧化应激水平的影响[J]. 医学研究杂志, 2016, 45(12): 57-61.
|
[27]
|
林欢欢, 宋成稳. 益生菌联合美沙拉嗪对溃疡性结肠炎患者氧化应激与炎性因子水平的影响[J]. 大医生, 2021, 6(23): 57-59.
|